Check omega 3 claims before buying
Low certaintyADHD evidence
Before paying for a supplement for your child's ADHD, talk through the evidence and the safety.
Start with the time you have
1 minute
Write down exactly what improvement you'd expect before paying for an ADHD supplement.
5 minutes
List the supplements and medicines you want a pharmacist to review.
15 minutes
Read the Cochrane summary and prepare questions about likely benefit, cost and safety.
How sure the science is
Low certainty, ADHD evidence
- The number could be quite different.
- Few trials, or trials with weak spots.
- Measured in people with ADHD.
- 15 trials
- 963 people
- children and teens
- parent rated
- 3 to 6 months
- measured on core ADHD symptoms
EBI-ADHD re-estimation: 15 trials, 963 young people, parent-rated core symptoms at medium-term follow-up.
The number, drawn
Why it matters
- EBI-ADHD found an almost zero estimated benefit from polyunsaturated fatty acids on parent-rated symptoms at about 26 weeks: SMD 0.049, with a 95% confidence interval from -0.101 to 0.198.
- Certainty was low, and the interval includes no benefit.
- The Cochrane review rated it high certainty that these supplements had no effect on parent-rated total symptoms in the medium term, SMD -0.08.
- So this evidence does not support promising that omega 3 supplements will improve your child's ADHD.
How to do it
- Ask which ADHD outcome the supplement claim rests on, and how certain the result is.
- Bring any supplements already used to a pharmacist or clinician review.
- Talk about nutrition separately from promises to treat ADHD.
- Discuss supplements with a clinician or pharmacist, especially alongside medicines.
- This is an evidence review, not a recommendation to self-treat.
Putting it into practice
In real life
- Ask a pharmacist to review a supplement already in your child's cupboard.
- Compare an advert's promise with the review's finding that a meaningful symptom benefit is not established.
Watch out for
- Common mistakeA tiny average estimate is no guarantee of improvement. Check the uncertainty as well as the headline.
- Common mistakeSupplement safety depends on the whole medicine list, so include non-prescription products in a review.
Trusted guides
How we rated it
- Evidence grade
- B Trials in ADHD with low certainty, or strong general health evidence with a sourced reason it matters more with ADHD.
- The number
- Low certainty: omega 3 barely differs from placebo on symptoms at about 26 weeks (SMD 0.049) (Gosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025)
- Benefit
- 32/100 An editorial priority for the general list, weighted by certainty. It does not predict what will happen for you.
- Effort
- Some effort
Sources
- Tier 1 guidelineSupplementary materials for EBI-ADHDGosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025
- Tier 1 guidelineBenefits and harms of ADHD interventions: umbrella review and platform for shared decision makingBMJ, 2025
- Tier 1 guidelinePolyunsaturated fatty acids (PUFA) supplements for attention deficit hyperactivity disorder (ADHD) in children and adolescentsCochrane, 2023
- Tier 1 guidelineMedication Safety and Your HealthCDC, 2024
- General information about ADHD, not a diagnosis or an individual treatment plan.
- Tailoring changes the order of suggestions; it does not assess you.
- Medication decisions belong with you and a qualified clinician.